NCT00519389View on ClinicalTrials.gov

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Pandemic Influenza
Interventions
BIOLOGICAL

H5N1 VLP Vaccine

Two doses - Day 0 \& Day 28

BIOLOGICAL

Placebo

Two doses - Day 0 \& Day 28

Trial Locations (1)

78209

Healthcare Discoveries, Inc., San Antonio

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT00519389 - Safety, Reactogenicity and Immunogenicity of an H5N1 VLP | Biotech Hunter | Biotech Hunter